Manifold Bio

Manifold Bio is a biotechnology company founded in 2019 by prominent biological engineers from Harvard Medical School and the Wyss Institute, including Professor George Church. Based in Allston, Massachusetts, the company focuses on developing innovative protein therapeutics. The company specializes in high-throughput in vivo drug design using its unique protein barcoding technology, mCodes. This technology enables the evaluation of multiple protein designs simultaneously, improving the efficiency of drug development. Manifold Bio is advancing a pipeline of targeting-enhanced protein therapeutics, particularly for neurological disorders, and has developed brain shuttles to facilitate drug delivery across the blood-brain barrier. Manifold Bio has raised $45.4 million in funding, including a $40 million Series A round in 2022, to support its drug programs and expand its protein engineering capabilities. The leadership team includes CEO Gleb Kuznetsov, PhD, and Chief Scientific Officer Pierce Ogden, PhD.